Multigene Panel Testing in a Large Cohort of Adults With Epilepsy: Diagnostic Yield and Clinically Actionable Genetic Findings.
Journal
Neurology. Genetics
ISSN: 2376-7839
Titre abrégé: Neurol Genet
Pays: United States
ID NLM: 101671068
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
15
07
2021
accepted:
04
11
2021
entrez:
20
12
2021
pubmed:
21
12
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Although genetic testing among children with epilepsy has demonstrated clinical utility and become a part of routine testing, studies in adults are limited. This study reports the diagnostic yield of genetic testing in adults with epilepsy. Unrelated individuals aged 18 years and older who underwent diagnostic genetic testing for epilepsy using a comprehensive, next-generation sequencing-based, targeted gene panel (range 89-189 genes) were included in this cross-sectional study. Clinical information, provided at the discretion of the ordering clinician, was reviewed and analyzed. Diagnostic yield was calculated for all individuals including by age at seizure onset and comorbidities based on clinician-reported information. The proportion of individuals with clinically actionable genetic findings, including instances when a specific treatment would be indicated or contraindicated due to a diagnostic finding, was calculated. Among 2,008 individuals, a diagnostic finding was returned for 218 adults (10.9%), with clinically actionable findings in 55.5% of diagnoses. The highest diagnostic yield was in adults with seizure onset during infancy (29.6%, 0-1 year), followed by in early childhood (13.6%, 2-4 years), late childhood (7.0%, 5-10 years), adolescence (2.4%, 11-17 years), and adulthood (3.7%, ≥18 years). Comorbid intellectual disability (ID) or developmental delay resulted in a high diagnostic yield (16.0%), most notably for females (19.6% in females vs 12.3% in males). Among individuals with pharmacoresistant epilepsy, 13.5% had a diagnostic finding, and of these, 57.4% were clinically actionable genetic findings. These data reinforce the utility of genetic testing for adults with epilepsy, particularly for those with childhood-onset seizures, ID, and pharmacoresistance. This is an important consideration due to longer survival and the complexity of the transition from pediatric to adult care. In addition, more than half of diagnostic findings in this study were considered clinically actionable, suggesting that genetic testing could have a direct impact on clinical management and outcomes.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Although genetic testing among children with epilepsy has demonstrated clinical utility and become a part of routine testing, studies in adults are limited. This study reports the diagnostic yield of genetic testing in adults with epilepsy.
METHODS
METHODS
Unrelated individuals aged 18 years and older who underwent diagnostic genetic testing for epilepsy using a comprehensive, next-generation sequencing-based, targeted gene panel (range 89-189 genes) were included in this cross-sectional study. Clinical information, provided at the discretion of the ordering clinician, was reviewed and analyzed. Diagnostic yield was calculated for all individuals including by age at seizure onset and comorbidities based on clinician-reported information. The proportion of individuals with clinically actionable genetic findings, including instances when a specific treatment would be indicated or contraindicated due to a diagnostic finding, was calculated.
RESULTS
RESULTS
Among 2,008 individuals, a diagnostic finding was returned for 218 adults (10.9%), with clinically actionable findings in 55.5% of diagnoses. The highest diagnostic yield was in adults with seizure onset during infancy (29.6%, 0-1 year), followed by in early childhood (13.6%, 2-4 years), late childhood (7.0%, 5-10 years), adolescence (2.4%, 11-17 years), and adulthood (3.7%, ≥18 years). Comorbid intellectual disability (ID) or developmental delay resulted in a high diagnostic yield (16.0%), most notably for females (19.6% in females vs 12.3% in males). Among individuals with pharmacoresistant epilepsy, 13.5% had a diagnostic finding, and of these, 57.4% were clinically actionable genetic findings.
DISCUSSION
CONCLUSIONS
These data reinforce the utility of genetic testing for adults with epilepsy, particularly for those with childhood-onset seizures, ID, and pharmacoresistance. This is an important consideration due to longer survival and the complexity of the transition from pediatric to adult care. In addition, more than half of diagnostic findings in this study were considered clinically actionable, suggesting that genetic testing could have a direct impact on clinical management and outcomes.
Identifiants
pubmed: 34926809
doi: 10.1212/NXG.0000000000000650
pii: NG2021017156
pmc: PMC8678910
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e650Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
J Mol Diagn. 2015 Sep;17(5):533-44
pubmed: 26207792
J Mol Diagn. 2019 Mar;21(2):318-329
pubmed: 30610921
NPJ Genom Med. 2018 May 10;3:13
pubmed: 29760947
Mov Disord. 2010 Feb 15;25(3):275-81
pubmed: 20063428
JAMA Pediatr. 2017 Sep 1;171(9):863-871
pubmed: 28759667
Epilepsia. 2019 Aug;60(8):1661-1669
pubmed: 31273778
Brain. 2020 Mar 1;143(3):e19
pubmed: 32203577
J Med Genet. 2021 Apr 2;:
pubmed: 33811133
Genet Med. 2019 Jan;21(1):114-123
pubmed: 29895855
Expert Rev Neurother. 2020 Mar;20(3):251-269
pubmed: 31941393
Nat Rev Neurol. 2020 Oct;16(10):527-528
pubmed: 32616899
Epilepsia. 2018 May;59(5):1062-1071
pubmed: 29655203
Epilepsia. 2020 Sep;61(9):2053-2054
pubmed: 32783195
Lancet Neurol. 2016 Sep;15(10):1075-88
pubmed: 27571159
Epilepsia. 2014 Oct;55(10):1659-66
pubmed: 25169716
Epilepsia. 2020 Jun;61(6):1234-1239
pubmed: 32427350
Front Genet. 2018 Feb 07;9:20
pubmed: 29467791
Pediatrics. 2017 Jun;139(Suppl 3):S194-S206
pubmed: 28814540
PeerJ. 2019 Dec 19;7:e8278
pubmed: 31875159
Yonsei Med J. 2019 Dec;60(12):1209-1215
pubmed: 31769253
MMWR Morb Mortal Wkly Rep. 2017 Aug 11;66(31):821-825
pubmed: 28796763
Epilepsia. 1994;35 Suppl 1:S43-50
pubmed: 8293723
Clin Genet. 2016 Aug;90(2):149-55
pubmed: 26748532
CNS Spectr. 2004 Feb;9(2):136-44
pubmed: 14999169
Clin Genet. 2019 Jan;95(1):95-111
pubmed: 29992546
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Genet Med. 2017 Oct;19(10):1105-1117
pubmed: 28492532
Neurology. 2017 Aug 29;89(9):893-899
pubmed: 28733343
Clin EEG Neurosci. 2020 Jan;51(1):61-69
pubmed: 31554424
Epilepsia. 2017 Sep;58(9):1502-1517
pubmed: 28681381
JAMA Pediatr. 2019 Jan 1;173(1):e182302
pubmed: 30398534
Epilepsia Open. 2019 Jul 01;4(3):397-408
pubmed: 31440721
Hum Mutat. 2009 Nov;30(11):1486-511
pubmed: 19862833
Epilepsia. 2016 May;57(5):757-69
pubmed: 27037674
Ann Neurol. 2015 Dec;78(6):949-57
pubmed: 26381753
Can J Neurol Sci. 2019 Jan;46(1):7-13
pubmed: 30419982